Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
US7601818B2 · kind B2 · utility
44Cited by
12References
26Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 15, 2004 |
| Grant date | Oct 13, 2009 |
| Priority date | — |
| Expiry date | Sep 5, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2842
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.